Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: A prospective observational studyAardema, H., Nannan Panday, P., Wessels, M., van Hateren, K., Dieperink, W., Kosterink, J. G. W., Alffenaar, J-W. & Zijlstra, J. G., Jul-2017, In : International journal of antimicrobial agents. 50, 1, p. 68-73 6 p.
Research output: Contribution to journal › Article › Academic › peer-review
Optimal dosing of β-lactam antibiotics in critically ill patients is a challenge given the unpredictable pharmacokinetic profile of this patient population. Several studies have shown intermittent dosing to often yield inadequate drug concentrations. Continuous dosing is an attractive alternative from a pharmacodynamic point of view. This study evaluated whether, during continuous dosing, piperacillin concentrations reached and maintained a pre-defined target in critically ill patients. Adult patients treated with piperacillin by continuous dosing in the intensive care unit of a university medical centre in The Netherlands were prospectively studied. Total and unbound piperacillin concentrations drawn at fixed time points throughout the entire treatment course were determined by liquid chromatography-tandem mass spectrometry. A pharmacokinetic combined target of a piperacillin concentration ≥80 mg/L, reached within 1 h of starting study treatment AND maintained throughout the treatment course, was set. Eighteen patients were analysed. The median duration of monitored piperacillin treatment was 60 h (interquartile range, 33-96 h). Of the 18 patients, 5 (27.8 %) reached the combined target; 15 (83.3%) reached and maintained a less strict target of >16 mg/L. In this patient cohort, this dosing schedule was insufficient to reach the pre-defined target. Depending on which target is to be met, a larger initial cumulative dose is desirable, combined with therapeutic drug monitoring.
|Number of pages||6|
|Journal||International journal of antimicrobial agents|
|Early online date||10-May-2017|
|Publication status||Published - Jul-2017|
- EFFICACY , PHARMACODYNAMICS, INTENSIVE-CARE-UNIT, CONTINUOUS VENOVENOUS HEMOFILTRATION, ILL PATIENTS, CONTINUOUS-INFUSION, SEVERE SEPSIS, SEPTIC SHOCK, PHARMACOKINETICS, TAZOBACTAM, beta-Lactam , Critical care, Continuous dosing, Piperacillin